Pharmaceutical industry – Page 10
-
Opinion
A red pill for green medicines
The pharmaceutical industry is taking action towards net zero
-
Business
Covid-19 antivirals surge forward
Promising results from Pfizer trial, while UK approves Merck & Co’s molnupiravir
-
Opinion
All work and no play
Is the long-hours culture of academic organic chemistry laboratories finally changing?
-
Article
Facilitating the future
A view from the top at Johnson Matthey on the future of drug development
-
Business
Predicting and preventing production losses with AI
Seebo’s machine learning technology helps chemical manufacturers get deep insight into their processes
-
Article
AstraZeneca explores new frontiers through academic collaborations
The important of partnerships between industry and academia to drive innovation
-
Business
New antiviral impresses against Covid-19
Merck & Co and Ridgeback’s molnupiravir reduces risk of hospitalisation and death, and may work against other coronaviruses
-
Opinion
Where are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments
-
Business
Fully synthetic proteins make tailored medicines
Bright Peak Therapeutics makes modified protein drugs from scratch
-
Webinar
Unlock the potential of definitive screening designs to drive your projects forward
In this webinar we help demystify DSDs and reveal how their complexity can be harnessed for manufacturing processes
-
Business
The future of ‘next generation’ DNA sequencing
As it gets cheaper and easier to read genetic code, its applications are expanding rapidly
-
Business
US judge accepts Purdue’s opioid bankruptcy settlement plan
Deal releases $4.3bn to combat addiction, but protects Sackler family from litigation
-
Business
US grants Pfizer’s Covid-19 vaccine full approval
WHO calls for delay to booster programmes to allow more global distribution
-
Business
The multi-pronged search for Covid-19 treatments
Drugs that block infection or reduce inflammation will complement vaccine protection
-
Opinion
The price of failure
Drug market structures and high R&D failure rates can tempt companies into bad pricing behaviour
-
Business
Budget cuts at UK medicines regulator raise eyebrows
MHRA to cut 300 jobs amid financial pressures arising from Brexit
-
Business
Brewing up plant-inspired medicines
Antheia reconstructs complex biochemical pathways in yeasts to speed up production of natural product-based drugs
-
Webinar
Find robust operating points using JMP’s Simulation Experiment tool
Learn how simulations can be used to minimise defect rate and improve crucial targets
-
Business
Developing countries sidelined in Covid-19 vaccine scramble
Lack of funds and local manufacturing capacity has prevented Covax from competing with wealthier nations’ self-interest
-
Article
People, partnerships, pharma: exploring the science of innovation
The importance of fostering collaborative cultures to accelerate innovation